Chapter 16.5 : Botulinum Toxin—

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.

Ebook: Choose a downloadable PDF or ePub file. Chapter is a downloadable PDF file. File must be downloaded within 48 hours of purchase

Buy this Chapter
Digital (?) $30.00

Preview this chapter:
Zoom in

Botulinum Toxin—, Page 1 of 2

| /docserver/preview/fulltext/10.1128/9781555818814/9781555818814_Chap16.5-1.gif /docserver/preview/fulltext/10.1128/9781555818814/9781555818814_Chap16.5-2.gif


organisms are straight to slightly curved, Gram-positive (in young cultures), motile, anaerobic rods, 0.5 to 2.0 μm in width and 1.6 to 22.0 μm in length, with oval, subterminal spores ( ). is a Select Agent Tier 1 organism. Sentinel clinical laboratories will not isolate nor identify or its toxins. In suspected cases of botulism, sentinel clinical laboratories will obtain appropriate specimens, ensure that they are packaged safely, and consult with the patient’s physician, their designated Laboratory Response Network (LRN) reference laboratory, and the CDC. Sentinel clinical laboratories are defined as those certified to perform high-complexity testing under the Clinical Laboratory Improvement Amendments of 1988 (CLIA’88) by the Centers for Medicare and Medicaid Services for the applicable microbiology specialty. Laboratory in-house testing includes Gram stains and at least one of the following: lower respiratory tract, wound, or blood cultures.

Citation: Leber A. 2016. Botulinum Toxin—, p 16.5.1-16.5.9. In Clinical Microbiology Procedures Handbook, Fourth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555818814.ch16.5
Highlighted Text: Show | Hide
Loading full text...

Full text loading...


Image of Figure 16.5–1
Figure 16.5–1

management flow chart

Citation: Leber A. 2016. Botulinum Toxin—, p 16.5.1-16.5.9. In Clinical Microbiology Procedures Handbook, Fourth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555818814.ch16.5
Permissions and Reprints Request Permissions
Download as Powerpoint


1. Stevens DL, Bryant AE, Berger A, von Eichel/Streiber C. 2011. Clostridium, p 834857. In Versalovic J, Carroll KC, Funke G, Jorgensen JH, Landry ML, Warnock DW (ed.), Manual of Clinical Microbiology, 10th ed. ASM Press, Washington, DC.
2. Hatheway CI. 2009. Botulism, p 111133. In Balows A, Hausler WJ, Ohashi M, Turano A (ed), Laboratory Diagnosis of Infectious Diseases. Springer, New York, NY.
3. Terranova W, Breman JG, Locey RP, Speck S. 1978. Botulism type B: epidemiologic aspects of an extensive outbreak. Am J Epidemiol 108:150156.
4. Woodruff BA, Griffin PM, McCroskey LM, Smart JF, Wainwright RB, Bryant RG, Hutwagner LC, Hatheway CL. 1992. Clinical and laboratory comparison of botulism from toxin types A, B, and E in the United States 1975-1988. J Infect Dis 166:12811286.
5. Shapiro RL, Hatheway C, Becher S, Swerdlow DL. 1997. Botulism surveillance and emergency response. A public health strategy for a global challenge. JAMA 278:433435.
6. Arnon SS, Schechter R, Inglesby TV, Henderson DA, Bartlett JG, Ascher MS, Eitzen E, Fine AD, Hauer J, Layton M, Lillibridge S, Osterholm MT, O’Toole T, Parker G, Perl TM, Russell PK, Swerdlow DL, Tonat K. 2001. Botulinum toxin as a biological weapon: medical and public health management. JAMA 285:10591070.
7. Shapiro RL, Hatheway C, Swerdlow DL. 1998. Botulism in the United States: a clinical and epidemiologic review. Ann Intern Med 129:221228.
8. Centers for Disease Control and Prevention. 1976. Follow-up: botulism associated with commercial cherry peppers. Morb Mortal Wkly Rep 25:148.
9. Centers for Disease Control and Prevention. 1998. Botulism in the United States, 1899-1996. Handbook For Epidemiologists, Clinicians, and Laboratory Workers. Centers for Disease Control and Prevention, Atlanta, GA.
10. Merson MH, Dowell VRJr. 1973. Epidemiologic, clinical and laboratory aspects of wound botulism. N Engl J Med 289:11051110.
11. Yuan J, Inami G, Mohle-Boetani J, Vugia DJ. 2011. Recurrent wound botulism among injection drug users in California. Clin Infect Dis 52:862866.
12. Arnon SS. 1992. Infant botulism, p 10951102. In Feigen R, Cherry J (ed), Textbook of Pediatric Infectious Diseases. W. B. Saunders, Philadelphia, PA.
13. Long SS, Gajewski JL, Brown LW, Gilligan PH. 1985. Clinical, laboratory, and environmental features of infant botulism in southeastern Pennsylvania. Pediatrics 75:935941.
14. Hughes JM, Blumenthal JR, Merson MH, Lombard GL, Dowell VRJr, Gangarosa EJ. 1981. Clinical features of types A and B foodborne botulism. Ann Intern Med 95:442445.
15. Angulo FJ, Getz J, Taylor JP, Hendricks KA, Hatheway CL, Barth SS, Solomon HM, Larson AE, Johnson EA, Nickey LN, Ries AA. 1998. A large outbreak of botulism: the hazardous baked potato. J Infect Dis 178:172177.
16. St. Louis ME, Peck SH, Bowering D, Morgan GB, Blatherwick J, Banerjee S, Kettyls GD, Black WA, Milling ME, Hauschild AH, Tauxe RV, Blake PA. 1988. Botulism from chopped garlic: delayed recognition of a major outbreak. Ann Intern Med 108:363-368.
17. Cato EP, George WL, Finegold SM. 1986. Genus Clostridium, Praemozski 1880, 23AL, p11411200. In Sneath PHA, Mair NS, Sharp ME, Holt JG (ed), Bergey’s Manual of Systematic Bacteriology, vol 2.Williams & Wilkins, Baltimore, MD.
18. Eitzen E, Pavlin J, Cieslak T, Christopher G, Culpepper R. 1998. Medical Management of Biological Casualties Handbook, 3rd ed. U.S. Army Medical Research Institute of Infectious Diseases, Fort Detrick, MD.
19. Tackett CO, Shandera WX, Mann JM, Hargrett NT, Blake PA. 1984. Equine antitoxin use and other factors that predict outcome in type A foodborne botulism. Am J Med 76:794798.
20. Hatheway CL. 1995. Botulism: the present status of the disease. Curr Top Microbiol Immunol 195:5575.
21. Miller JM. 2000. The Laboratory Response to Agents of Bioterrorism. American Society for Microbiology Audioconference Series. American Society for Microbiology, Washington, DC.
22. Gilchrist MJR, McKinney WP, Miller JM, Weissfeld AS. 2000. Cumitech 33, Laboratory Safety, Management and Diagnosis of Biological Agents Associated with Bioterrorism. Coordinating ed, Snyder JW. ASM Press, Washington, DC.
23. Centers for Disease Control and Prevention. 2010. Investigational heptavalent botulinum antitoxin (HBAT) to replace licensed antitoxin AB and investigational botulinum antitoxin E. MMWR Morb Mortal Wkly Rep 59:299.
24. Arnon SS, Barzilay EJ. 2009. Clostridial infections: botulism and infant botulism, p 259262. In Pickering LK, Baker CJ, Kimberlin DW, Long SS (ed), The Red Book: 2009 Report of the Committee on Infectious Diseases. American Academy of Pediatrics, Elk Grove Village, IL.
25. Arnon SS, Schechter R, Maslanka SE, Jewell NP, Hatheway CL. 2006. Human botulism immune globulin for the treatment of infant botulism. N Engl J Med 354:462471.
26. Infectious Diseases Society of America. 2002. Bioterrorism information and resources. http://www.idsociety.org.


Generic image for table
Table 16.5–1

Collection and transport of clinical specimens for laboratory testing and confirmation

Citation: Leber A. 2016. Botulinum Toxin—, p 16.5.1-16.5.9. In Clinical Microbiology Procedures Handbook, Fourth Edition. ASM Press, Washington, DC. doi: 10.1128/9781555818814.ch16.5

This is a required field
Please enter a valid email address
Please check the format of the address you have entered.
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error